tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

APRE Stock Latest News

UPDATE – Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
Press ReleasesUPDATE – Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
10d ago
APRE
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
PremiumPress Releases
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
10d ago
APRE
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
PremiumPress Releases
Aprea Therapeutics to Present at the H.C. Wainwright Annual Global Investment Conference
23d ago
APRE
Aprea Therapeutics management to meet virtually with B. Riley
PremiumThe Fly
Aprea Therapeutics management to meet virtually with B. Riley
1M ago
APRE
Aprea Therapeutics management to meet virtually with B. Riley
PremiumThe Fly
Aprea Therapeutics management to meet virtually with B. Riley
1M ago
APRE
Aprea Therapeutics sees cash runway into 4Q25
PremiumThe FlyAprea Therapeutics sees cash runway into 4Q25
1M ago
APRE
Aprea Therapeutics reports Q2 EPS (58c) vs. (87c) last year
Premium
The Fly
Aprea Therapeutics reports Q2 EPS (58c) vs. (87c) last year
1M ago
APRE
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
Premium
Press Releases
Aprea Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
1M ago
APRE
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
PremiumPress Releases
Aprea Therapeutics to Host Virtual KOL Event on APR-1051, a Highly Selective and Potentially Best-in-Class Oral WEE1 Inhibitor, on Monday, June 24, 2024
3M ago
APRE
Aprea Therapeutics announces first patient dosed in ACESOT-1051 Phase I trial
PremiumThe Fly
Aprea Therapeutics announces first patient dosed in ACESOT-1051 Phase I trial
3M ago
APRE
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
PremiumPress Releases
Aprea Therapeutics Announces First Patient Dosed in ACESOT-1051 Phase 1 Trial Evaluating Oral WEE1 Inhibitor APR-1051
3M ago
APRE
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
PremiumPress Releases
Aprea Therapeutics Announces that Safety Review Committee (SRC) Endorses Dosing of Patients with ATRN-119 at 800 mg Once Daily in Ongoing ABOYA-119 Clinical Trial
4M ago
APRE
Aprea announces SRC enhances dosing of patients with ATRN-119 at 800 mg
PremiumThe FlyAprea announces SRC enhances dosing of patients with ATRN-119 at 800 mg
4M ago
APRE
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
Premium
Press Releases
Aprea Therapeutics Reports First quarter 2024 Financial Results and Provides a Business Update
4M ago
APRE
Aprea Therapeutics reports Q1 EPS (67c) vs ($1.34) last year
Premium
The Fly
Aprea Therapeutics reports Q1 EPS (67c) vs ($1.34) last year
4M ago
APRE
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
PremiumPress Releases
Aprea Therapeutics to Attend the 2024 RBC Capital Markets Global Healthcare Conference
4M ago
APRE
APRE Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
APRE Upcoming Earnings Report: What to Expect?
4M ago
APRE
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
PremiumPress Releases
Aprea Therapeutics Announces Appointment of Nadeem Q. Mirza, M.D., M.P.H. as Chief Medical Officer and Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
5M ago
APRE
Aprea Therapeutics appoints Mirza as Chief Medical Officer
PremiumThe Fly
Aprea Therapeutics appoints Mirza as Chief Medical Officer
5M ago
APRE
SLRX
Aprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
PremiumPress ReleasesAprea Therapeutics Announces Presentations on its Next Generation WEE1 Inhibitor, APR-1051, and A Novel Macrocyclic ATR Inhibitor, ATRN-119, at AACR Annual Meeting 2024
5M ago
APRE
Aprea Therapeutics files to sell 4.39M shares of common stock for holders
Premium
The Fly
Aprea Therapeutics files to sell 4.39M shares of common stock for holders
6M ago
APRE
Aprea Therapeutics price target raised to $11 from $9 at Wedbush
Premium
The Fly
Aprea Therapeutics price target raised to $11 from $9 at Wedbush
6M ago
APRE

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >